4.7 Review

Personalized nanomedicine for CNS diseases

期刊

DRUG DISCOVERY TODAY
卷 23, 期 5, 页码 1007-1015

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2017.11.010

关键词

-

资金

  1. NIH [RO1DA042706, R01DA040537, RO1DA037838, RO1DA034547]
  2. Institute of Neurolmmune Pharmacology (INIP) of Florida International University
  3. Advanced Materials Engineering Research Institute (AMERI) of Florida International University

向作者/读者索取更多资源

Central nervous system (CNS) diseases are rapidly increasing globally. Currently used therapeutic agents to treat CNS diseases exhibit significant efficacy. However, the inability of these drugs to cross the blood brain barrier (BBB) and invasiveness of the technologies to achieve localized drug delivery in disease specific parts of the brain have thwarted pain-free and complete treatment of CNS diseases. Therefore, the safe, non-invasive, and targeted delivery of drugs to the brain using nanoparticles (NPs) is currently receiving considerable research attention. Here, we highlight advances in state-of-the-art personalized nanomedicine for the treatment of CNS diseases (with a focus on dementia), the related challenges, possible solutions, and prospects for nano-enabled personalized medicine.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据